验证大型管理数据库的需要:退伍军人健康管理局的ICD-9CM编码的渗出性年龄相关性黄斑变性和雷尼单抗的使用。

Paul Latkany, Mona Duggal, Joseph Goulet, Hyung Paek, Michael Rambo, Philip Palmisano, Woody Levin, Joseph Erdos, Amy Justice, Cynthia Brandt
{"title":"验证大型管理数据库的需要:退伍军人健康管理局的ICD-9CM编码的渗出性年龄相关性黄斑变性和雷尼单抗的使用。","authors":"Paul Latkany,&nbsp;Mona Duggal,&nbsp;Joseph Goulet,&nbsp;Hyung Paek,&nbsp;Michael Rambo,&nbsp;Philip Palmisano,&nbsp;Woody Levin,&nbsp;Joseph Erdos,&nbsp;Amy Justice,&nbsp;Cynthia Brandt","doi":"10.1007/s12177-010-9052-4","DOIUrl":null,"url":null,"abstract":"<p><p>We performed a validation study by chart review of data for exudative age-related macular degeneration (eAMD) and, because of the Veterans Administration (VA) therapy policy, ranibizumab usage in the largest electronic medical record system in the USA. We reviewed 5,854 distinct patients who visited an ophthalmology clinic within VA Connecticut from January 2006-December 2008. We randomly selected 98 of 138 distinct eAMD patients and 265 of 5,588 non-eAMD patients who did not receive ranibizumab. International Classification of Diseases, Ninth Revision, Clinical Modification coding of eAMD had an excellent positive predictive value of 97.8% (95% confidence interval (CI), 93.5-99.4%). The national Decision Support System (DSS) had an excellent positive predictive value of 100% (95% CI, 79.9-100%) for ranibizumab. However, the negative predictive value of the DSS dispensed ranibizumab decreased to 67.5 (95% CI, 62.1-72.4) because of a change in the way local values were stored that led to errors. Therefore, validation of clinical information over time in large databases is necessary.</p>","PeriodicalId":73873,"journal":{"name":"Journal of ocular biology, diseases, and informatics","volume":"3 1","pages":"30-4"},"PeriodicalIF":0.0000,"publicationDate":"2010-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s12177-010-9052-4","citationCount":"7","resultStr":"{\"title\":\"The need for validation of large administrative databases: Veterans Health Administration ICD-9CM coding of exudative age-related macular degeneration and ranibizumab usage.\",\"authors\":\"Paul Latkany,&nbsp;Mona Duggal,&nbsp;Joseph Goulet,&nbsp;Hyung Paek,&nbsp;Michael Rambo,&nbsp;Philip Palmisano,&nbsp;Woody Levin,&nbsp;Joseph Erdos,&nbsp;Amy Justice,&nbsp;Cynthia Brandt\",\"doi\":\"10.1007/s12177-010-9052-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>We performed a validation study by chart review of data for exudative age-related macular degeneration (eAMD) and, because of the Veterans Administration (VA) therapy policy, ranibizumab usage in the largest electronic medical record system in the USA. We reviewed 5,854 distinct patients who visited an ophthalmology clinic within VA Connecticut from January 2006-December 2008. We randomly selected 98 of 138 distinct eAMD patients and 265 of 5,588 non-eAMD patients who did not receive ranibizumab. International Classification of Diseases, Ninth Revision, Clinical Modification coding of eAMD had an excellent positive predictive value of 97.8% (95% confidence interval (CI), 93.5-99.4%). The national Decision Support System (DSS) had an excellent positive predictive value of 100% (95% CI, 79.9-100%) for ranibizumab. However, the negative predictive value of the DSS dispensed ranibizumab decreased to 67.5 (95% CI, 62.1-72.4) because of a change in the way local values were stored that led to errors. Therefore, validation of clinical information over time in large databases is necessary.</p>\",\"PeriodicalId\":73873,\"journal\":{\"name\":\"Journal of ocular biology, diseases, and informatics\",\"volume\":\"3 1\",\"pages\":\"30-4\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2010-07-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1007/s12177-010-9052-4\",\"citationCount\":\"7\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of ocular biology, diseases, and informatics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s12177-010-9052-4\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of ocular biology, diseases, and informatics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12177-010-9052-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 7

摘要

我们通过对渗出性年龄相关性黄斑变性(eAMD)数据的图表回顾进行了一项验证研究,并且由于退伍军人管理局(VA)的治疗政策,在美国最大的电子病历系统中使用了雷尼单抗。我们回顾了2006年1月至2008年12月期间在弗吉尼亚州康涅狄格眼科诊所就诊的5854名不同的患者。我们随机选择138例不同eAMD患者中的98例和5588例未接受雷尼单抗治疗的非eAMD患者中的265例。《国际疾病分类》第九版临床修改编码eAMD的极好阳性预测值为97.8%(95%置信区间(CI), 93.5 ~ 99.4%)。国家决策支持系统(DSS)对雷尼单抗的阳性预测值为100% (95% CI, 79.9-100%)。然而,DSS分配的雷尼单抗的阴性预测值下降到67.5 (95% CI, 62.1-72.4),因为局部值存储方式的改变导致了错误。因此,在大型数据库中验证临床信息是必要的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

The need for validation of large administrative databases: Veterans Health Administration ICD-9CM coding of exudative age-related macular degeneration and ranibizumab usage.

The need for validation of large administrative databases: Veterans Health Administration ICD-9CM coding of exudative age-related macular degeneration and ranibizumab usage.

We performed a validation study by chart review of data for exudative age-related macular degeneration (eAMD) and, because of the Veterans Administration (VA) therapy policy, ranibizumab usage in the largest electronic medical record system in the USA. We reviewed 5,854 distinct patients who visited an ophthalmology clinic within VA Connecticut from January 2006-December 2008. We randomly selected 98 of 138 distinct eAMD patients and 265 of 5,588 non-eAMD patients who did not receive ranibizumab. International Classification of Diseases, Ninth Revision, Clinical Modification coding of eAMD had an excellent positive predictive value of 97.8% (95% confidence interval (CI), 93.5-99.4%). The national Decision Support System (DSS) had an excellent positive predictive value of 100% (95% CI, 79.9-100%) for ranibizumab. However, the negative predictive value of the DSS dispensed ranibizumab decreased to 67.5 (95% CI, 62.1-72.4) because of a change in the way local values were stored that led to errors. Therefore, validation of clinical information over time in large databases is necessary.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信